Copy to clipboard 
SeaSpine announced 1Q17 revenue of US $31.9MM, +1.6% vs. 1Q16.
| 1Q17 | 1Q16 | $ Change | % Change | |
| Â Spine | $14.8Â | $14.7Â | $0.0Â | 0.2%Â |
| Â Orthobiologics | $17.1Â | $16.7Â | $0.5Â | 2.8%Â |
| Total  | $31.9 | $31.4 | $0.5 | 1.6% |
Geographic results: U.S. $28.6MM, +0.2%; ex-U.S. $3.3MM, +15.6%
1Q17 performance highlights:
- Increase in orthobiologics driven by U.S. and ex-U.S. sales, primarily due to addition of new distributors
- U.S. orthobiologic revenue buoyed by growth in Latin America and Europe
- Spinal hardware revenue growth supported by addition of new Latin America distributor
- U.S. spinal hardware impacted by lower demand for older products (particularly interbody fusion)
- Launched >10 new products in 2016 (primarily hardware), planning 8-10 new/next-gen products and line extensions in 2017, including up to 3 orthobiologic products (e.g. DBM Fibers, Resorbable Mesh DBM system—latter could launch in early 2018)
- Reaching end of limited launch for Shoreline standalone anterior cervical system and Mariner next-gen modular pedicle screw, both FDA-cleared in 4Q16; full launch slated for mid-year 2017
- Mid-year limited launch planned for Skipjack expandable interbody device (based on IP acquired from NLT Spine in 3Q16)
- In 2Q, launched Daytona Small Stature Pediatric Deformity System and alpha-launched reusable Rapid Graft Delivery System
- Legacy distributor disruption is outpaced by new distributors, breadth of new products launched in 2016
Sources: SeaSpine Holdings Corporation; ORTHOWORLD Inc.
SeaSpine announced 1Q17 revenue of US $31.9MM, +1.6% vs. 1Q16.
Q17Â
Q16Â
$ ChangeÂ
% ChangeÂ
 Spine
$14.8Â
$14.7Â
$0.0Â
0.2%Â
 Orthobiologics
$17.1Â
$16.7Â ...
SeaSpine announced 1Q17 revenue of US $31.9MM, +1.6% vs. 1Q16.
| 1Q17 | 1Q16 | $ Change | % Change | |
| Â Spine | $14.8Â | $14.7Â | $0.0Â | 0.2%Â |
| Â Orthobiologics | $17.1Â | $16.7Â | $0.5Â | 2.8%Â |
| Total  | $31.9 | $31.4 | $0.5 | 1.6% |
Geographic results: U.S. $28.6MM, +0.2%; ex-U.S. $3.3MM, +15.6%
1Q17 performance highlights:
- Increase in orthobiologics driven by U.S. and ex-U.S. sales, primarily due to addition of new distributors
- U.S. orthobiologic revenue buoyed by growth in Latin America and Europe
- Spinal hardware revenue growth supported by addition of new Latin America distributor
- U.S. spinal hardware impacted by lower demand for older products (particularly interbody fusion)
- Launched >10 new products in 2016 (primarily hardware), planning 8-10 new/next-gen products and line extensions in 2017, including up to 3 orthobiologic products (e.g. DBM Fibers, Resorbable Mesh DBM system—latter could launch in early 2018)
- Reaching end of limited launch for Shoreline standalone anterior cervical system and Mariner next-gen modular pedicle screw, both FDA-cleared in 4Q16; full launch slated for mid-year 2017
- Mid-year limited launch planned for Skipjack expandable interbody device (based on IP acquired from NLT Spine in 3Q16)
- In 2Q, launched Daytona Small Stature Pediatric Deformity System and alpha-launched reusable Rapid Graft Delivery System
- Legacy distributor disruption is outpaced by new distributors, breadth of new products launched in 2016
Sources: SeaSpine Holdings Corporation; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
